Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > December 21, 2023
Daily News
December 21, 2023
- Pharma Trade Groups Applaud FY2024 Drug Pricing Reform Outline
December 21, 2023
- Chuikyo OKs Outline of FY2024 Drug Pricing Reform; No Unprofitability Re-Pricing for 7%-Plus Price Gap
December 21, 2023
- Health Ministry Panel OKs Inclusion of 5-in-1 Jab in NIP from Next April
December 21, 2023
- Ono, UK DRI to Partner in Dementia Drug Discovery Research
December 21, 2023
- Maruishi Gains Japan Rights to Allay’s Postoperative Pain Relief Drug
December 21, 2023
- JMA, JDA, JPA Call for Mitigation Measures for New LLP Coverage Rule
December 21, 2023
- Japan to Roll Out New LLP Coverage Rule in October; 18 Billion Yen Saving Eyed for FY2024
December 21, 2023
- JCR, Alexion Tie Up to Develop Oligonucleotide Therapeutics
December 21, 2023
- Masaki Ogushi Promoted to Chief of LDP’s Health Division
December 21, 2023
- JCR, Takeda Wind Up Collab on Gene Therapy Research
December 21, 2023
- Generic Use Rate Hits Record 82.2% in July-September: JGA
December 21, 2023
- Shionogi’s Novel Antibiotic Fetroja Now Available in Japan
December 21, 2023
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…